S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aphria Inc. stock logo
APHA
Aphria
$15.38
$15.48
$2.78
$32.29
$4.87B2.6721.83 million shsN/A
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
C$5.86
+1.6%
C$5.48
C$4.35
C$5.95
C$592.86M0.4976,098 shs58,974 shs
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
C$4.89
-1.0%
C$4.22
C$3.34
C$7.12
C$156.09M1.1610,113 shs5,800 shs
Organigram Holdings Inc. stock logo
OGI
Organigram
$1.83
-2.7%
$2.11
$0.97
$2.91
$188.86M1.091.38 million shs1.43 million shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aphria Inc. stock logo
APHA
Aphria
0.00%0.00%0.00%0.00%0.00%
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
+0.17%+3.59%+8.87%+2.49%+19.71%
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
-1.01%-2.00%+22.25%+20.74%-17.95%
Organigram Holdings Inc. stock logo
OGI
Organigram
0.00%-10.05%-9.18%+6.21%-15.91%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aphria Inc. stock logo
APHA
Aphria
N/AN/AN/AN/AN/AN/AN/AN/A
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
1.3225 of 5 stars
2.50.00.00.02.53.30.6
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
0.0672 of 5 stars
1.10.01.70.00.90.80.0
Organigram Holdings Inc. stock logo
OGI
Organigram
0.3033 of 5 stars
0.02.00.00.03.10.01.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aphria Inc. stock logo
APHA
Aphria
N/AN/AN/AN/A
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
3.00
BuyC$6.5812.34% Upside
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
2.25
HoldC$4.58-6.44% Downside
Organigram Holdings Inc. stock logo
OGI
Organigram
3.00
BuyN/AN/A

Current Analyst Ratings

Latest APHA, GUD, EOF, HLS, and OGI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Organigram Holdings Inc. stock logo
OGI
Organigram
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
3/22/2024
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperformC$6.50 ➝ C$7.00
3/18/2024
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetC$6.50 ➝ C$5.00
3/15/2024
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetC$4.35 ➝ C$4.15
3/6/2024
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperformC$7.00 ➝ C$7.50
2/28/2024
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperformC$7.00
2/22/2024
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetC$5.00 ➝ C$4.35
2/6/2024
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
Clarus Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aphria Inc. stock logo
APHA
Aphria
$405.96M12.00$0.09 per share166.43$4.80 per share3.20
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
C$328.20M1.81C$1.52 per share3.85C$7.38 per share0.79
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
C$63.07M2.47C$0.32 per share15.22C$3.06 per share1.60
Organigram Holdings Inc. stock logo
OGI
Organigram
$120.01M1.57N/AN/A$2.48 per share0.74

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aphria Inc. stock logo
APHA
Aphria
-$63.21M-$0.06N/A219.71N/A-36.10%-2.30%-1.66%N/A
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
-C$16.84M-C$0.16N/AN/A-5.13%-2.14%0.40%5/9/2024 (Estimated)
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
-C$27.53M-C$1.16N/AN/A-43.65%-24.69%-2.87%5/9/2024 (Estimated)
Organigram Holdings Inc. stock logo
OGI
Organigram
-$184.34M-$0.80N/AN/AN/A-173.48%-30.94%-27.70%4/23/2024 (Estimated)

Latest APHA, GUD, EOF, HLS, and OGI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/21/2024Q4 2023
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
C$0.02-C$0.03-C$0.05C$0.17C$78.37 millionC$74.20 million
3/14/2024Q4 2023
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
-C$0.13-C$0.18-C$0.05-C$0.13C$21.83 millionC$21.60 million
2/13/2024Q1 2024
Organigram Holdings Inc. stock logo
OGI
Organigram
-$0.10-$0.14-$0.04-$0.14$28.61 million$26.78 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aphria Inc. stock logo
APHA
Aphria
N/AN/AN/AN/AN/A
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
N/AN/AN/AN/AN/A
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
C$0.204.09%N/AN/A N/A
Organigram Holdings Inc. stock logo
OGI
Organigram
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aphria Inc. stock logo
APHA
Aphria
0.25
2.36
1.17
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
9.25
3.20
1.79
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
89.69
1.65
1.01
Organigram Holdings Inc. stock logo
OGI
Organigram
N/A
4.28
2.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aphria Inc. stock logo
APHA
Aphria
10.30%
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
13.67%
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
59.62%
Organigram Holdings Inc. stock logo
OGI
Organigram
34.63%

Insider Ownership

CompanyInsider Ownership
Aphria Inc. stock logo
APHA
Aphria
N/A
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
46.45%
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
0.49%
Organigram Holdings Inc. stock logo
OGI
Organigram
0.09%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aphria Inc. stock logo
APHA
Aphria
1,200316.80 millionN/AOptionable
Knight Therapeutics Inc. stock logo
GUD
Knight Therapeutics
725101.17 millionN/ANot Optionable
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
9131.92 millionN/ANot Optionable
Organigram Holdings Inc. stock logo
OGI
Organigram
984103.20 million103.11 millionOptionable

APHA, GUD, EOF, HLS, and OGI Headlines

SourceHeadline
Organigram (NASDAQ:OGI) Upgraded by Alliance Global Partners to "Buy"Organigram (NASDAQ:OGI) Upgraded by Alliance Global Partners to "Buy"
americanbankingnews.com - April 16 at 4:50 AM
Organigram (NASDAQ:OGI) Lifted to Buy at Alliance Global PartnersOrganigram (NASDAQ:OGI) Lifted to Buy at Alliance Global Partners
marketbeat.com - April 15 at 9:11 AM
Analysts Are Bullish on These Healthcare Stocks: Tonix Pharma (TNXP), OrganiGram Holdings (OGI)Analysts Are Bullish on These Healthcare Stocks: Tonix Pharma (TNXP), OrganiGram Holdings (OGI)
markets.businessinsider.com - April 11 at 1:36 PM
Organigram Recognized for Executive Gender Diversity by the Globe & Mails Women Lead Here Report for the Fourth Consecutive YearOrganigram Recognized for Executive Gender Diversity by the Globe & Mail's Women Lead Here Report for the Fourth Consecutive Year
stockhouse.com - April 10 at 5:10 PM
Q2 2024 EPS Estimates for Organigram Holdings Inc. Increased by Atb Cap Markets (NASDAQ:OGI)Q2 2024 EPS Estimates for Organigram Holdings Inc. Increased by Atb Cap Markets (NASDAQ:OGI)
marketbeat.com - April 5 at 8:21 AM
Organigram’s Popular SHRED Brand Surpasses $200 Million in Yearly Retail SalesOrganigram’s Popular SHRED Brand Surpasses $200 Million in Yearly Retail Sales
finance.yahoo.com - April 3 at 8:37 AM
Organigrams Popular SHRED Brand Surpasses $200 Million in Yearly Retail SalesOrganigram's Popular SHRED Brand Surpasses $200 Million in Yearly Retail Sales
businesswire.com - April 3 at 8:06 AM
Organigram Successfully Closes Previously Announced Underwritten Public OfferingOrganigram Successfully Closes Previously Announced Underwritten Public Offering
businesswire.com - April 2 at 8:51 AM
Organigram (NASDAQ:OGI) Stock Price Down 6.3%Organigram (NASDAQ:OGI) Stock Price Down 6.3%
marketbeat.com - March 30 at 12:43 AM
Why OrganiGram (OGI) Might Surprise This Earnings SeasonWhy OrganiGram (OGI) Might Surprise This Earnings Season
zacks.com - March 28 at 9:56 AM
Why OrganiGram (OGI) Stock Is DivingWhy OrganiGram (OGI) Stock Is Diving
msn.com - March 27 at 3:18 PM
Organigram Sells Units to Raise C$25 MIllionOrganigram Sells Units to Raise C$25 MIllion
newcannabisventures.com - March 27 at 10:18 AM
Organigram Announces Pricing of Overnight Marketed Public OfferingOrganigram Announces Pricing of Overnight Marketed Public Offering
businesswire.com - March 27 at 8:56 AM
Organigram Announces Launch of Overnight Marketed Public OfferingOrganigram Announces Launch of Overnight Marketed Public Offering
businesswire.com - March 26 at 7:06 PM
Organigram Invests in U.S. Based Open Book Extracts Representing Inaugural Jupiter InvestmentOrganigram Invests in U.S. Based Open Book Extracts Representing Inaugural Jupiter Investment
businesswire.com - March 26 at 1:36 PM
OGI Sep 2024 6.000 callOGI Sep 2024 6.000 call
finance.yahoo.com - March 26 at 12:10 AM
OGI Jun 2024 4.000 putOGI Jun 2024 4.000 put
finance.yahoo.com - March 26 at 12:10 AM
Organigram ‘assessing options’ after unfavorable ruling on cannabis ediblesOrganigram ‘assessing options’ after unfavorable ruling on cannabis edibles
mjbizdaily.com - March 26 at 12:10 AM
The Marijuana Stocks Could See A Rise This WeekThe Marijuana Stocks Could See A Rise This Week
marijuanastocks.com - March 24 at 9:40 AM
Organigram Receives Health Canadas Final Redetermination on JoltsOrganigram Receives Health Canada's Final Redetermination on Jolts
businesswire.com - March 22 at 7:00 PM
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $5Finding the Next Big Winners: 3 Stocks You Can Snag for Under $5
investorplace.com - March 21 at 4:05 PM
OGI Apr 2024 2.000 putOGI Apr 2024 2.000 put
finance.yahoo.com - March 17 at 12:08 AM
Top Marijuana Stocks For Trading Today 2024Top Marijuana Stocks For Trading Today 2024
marijuanastocks.com - March 6 at 9:06 AM
2 Top Marijuana Penny Stocks with High Momentum Before March 20242 Top Marijuana Penny Stocks with High Momentum Before March 2024
marijuanastocks.com - March 2 at 11:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aphria logo

Aphria

NASDAQ:APHA
Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.
Knight Therapeutics logo

Knight Therapeutics

TSE:GUD
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
HLS Therapeutics logo

HLS Therapeutics

TSE:HLS
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Organigram logo

Organigram

NASDAQ:OGI
Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.